Market Research Future has published a half-cooked research report on the global
Doxorubicin market. The global doxorubicin market accounts for USD 916.5 million in 2017
and expected to register steady growth rate of 6.5% during the forecast period.
Market Highlights:
Doxorubicin is a type of chemotherapy medicine called an anthracycline. It is used to reduce
or diminish the growth of cancer cells by blocking an enzyme called topo isomerase. Factors
that are propelling the growth of the doxorubicin market are surge in geriatric population,
rising prevalence of different types of cancer, increasing awareness for cancer treatment.
According to the International Federation of Pharmaceutical Manufacturers & Associations,
global pharmaceutical industry has spent more than USD 149.8 billion on pharmaceutical
Research and development activities.
The various side effects, cost containment policies by various governments, stringent
regulatory environment for product approval, are likely to hinder market growth during the
forecast period.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/7376
Key Players:
Some of the key players in the global Doxorubicin market are Doxorubicin market are Pfizer,
Inc, Sun Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Accord Healthcare,
Novartis AG, Sandoz, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceuticals, GLENMARK
PHARMACEUTICALS LTD. and various others
Segmentation:
The global doxorubicin market has been segmented on the basis of application, and
distribution channel.
The application segment is divided into liver cancer, gastric cancer, breast cancer, bone
sarcoma, prostate cancer, stomach cancer, ovarian cancer, leukemia and others.
The market, by distribution channel, has been segmented into hospital pharmacy, retail
pharmacy and others.
Regional Analysis:
The American market is expected to dominate the global doxorubicin market during the
forecast period due to the presence of major manufacturers, increase in number of cancer
cases, awareness for the treatment of cancer, and favorable reimbursement and regulatory
authorities. The European market is expected to be the second-largest due to growing pool
of cancer patients and rising healthcare expenditure. Moreover, the market in Asia-Pacific is
anticipated to be the fastest-growing during the forecast period owing to the increasing
geriatric population in countries such as India and China, increasing awareness programs for
the treatment of cancer, government initiatives and investment for the development of
healthcare sector and increasing number manufacturers finding opportunities in developing
countries. The market in the Middle East & Africa is likely to account for the smallest share
of the global doxorubicin market.
Browse Complete Report @ https://www.marketresearchfuture.com/reports/doxorubicin-
market-7376